SCHEMBL8619979

SCHEMBL8619979

COc1ccc(OC(Cc2ccccc2)CC(P(=O)(O)O)S(=O)(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
ACP3 P15309 1/20 0.44
MMP1 P03956 4/20 0.42
MMP13 P45452 2/20 0.42
MMP9 P14780 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
MMP2 P08253 3/20 0.41
MMP3 P08254 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
LDHA P00338 1/20 0.40
LAP3 P28838 2/20 0.39
HTT P42858 1/20 0.39
KEAP1 Q14145 1/20 0.39
FPR2 P25090 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8618892 0.91 LAP3 (0.43) PPARGPPARAACP3LAP3ANPEP
SCHEMBL8619819 0.91 LAP3 (0.43) PPARGPPARAACP3LAP3ANPEP
SCHEMBL8621232 0.91 LAP3 (0.43) PPARGPPARAACP3LAP3ANPEP
SCHEMBL8620141 0.91 PPARG (0.46) PPARGPPARAACP3LAP3ANPEP
SCHEMBL8626363 0.90 MTNR1A (0.42) PPARGPPARA
SCHEMBL8626353 0.88 PPARG (0.49) PPARGPPARAACP3LAP3CA12
SCHEMBL8619853 0.88 PPARA (0.49) PPARGPPARAACP3LAP3ANPEP
SCHEMBL8620802 0.87 PPARG (0.42) PPARGPPARAMMP13MMP9MMP2
SCHEMBL8621703 0.85 PPARG (0.51) PPARGPPARAACP3LAP3ANPEP
SCHEMBL8625112 0.84 PPARG (0.43) PPARGPPARAACP3ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US claimed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US claimed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP claimed
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US disclosed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed